Survival, response rates, and post-transplant outcomes in patients with Acute Myeloid Leukemia aged 60-75 treated with high intensity chemotherapy vs. lower intensity targeted therapy
The United States Food and Drug Administration has approved several oral, targeted therapies for the treatment of Acute Myeloid Leukemia (AML) in recent years. These agents are approved in patients with relapsed/refractory disease or as frontline therapy in patients who are ineligible for intensive...
Main Authors: | Kieran Sahasrabudhe, Ying Huang, Melanie Rebechi, Patrick Elder, Alice Mims, Sarah Wall |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2022-10-01
|
Series: | Frontiers in Oncology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.1017194/full |
Similar Items
-
Salvage Therapy after Allogeneic Hematopoietic Cell Transplantation: Targeted and Low-Intensity Treatment Options in Myelodysplastic Syndrome and Acute Myeloid Leukemia
by: Katie Culos, et al.
Published: (2019-05-01) -
Healthcare Resource Utilization among Patients between 60–75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
by: Antonio Solana-Altabella, et al.
Published: (2022-04-01) -
Comparison of Myeloablative Versus Reduced-Intensity Conditioning Regimens for Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia: A Cohort Study
by: Rafiye Çiftçiler, et al.
Published: (2019-05-01) -
Validation of the 2022 European LeukemiaNet risk stratification for acute myeloid leukemia
by: Ga-Young Song, et al.
Published: (2024-04-01) -
Effective use of intensive treatment against multiple myeloma of recipient origin after allogeneic transplantation for acute myeloid leukemia
by: Félicité de Charry, et al.
Published: (2023-01-01)